insights_auto
Outlook: 28.0% bullish·4.0% bearish
Go to analysischevron_right
GSK:NYSE
GSK plc
၄၈.၅၈ US$
arrow_downward
-၁.၃၆%(-၀.၆၇) 1D
၄၈.၁၆ US$
arrow_downward
-၀.၈၆% (-၀.၄၂)todayPre-market
Closed: နို ၁၈, GMT-၅ ၁၆:၀၀:၀၂ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GSK...
Open
၄၉.၀၃ US$
High
၄၉.၄၉ US$
Low
၄၈.၅၄ US$
Mkt. cap
ဋေ ၉.၈၃ ထ
Avg. vol.
၄.၈၂ သန်း
Volume
၈.၉၆ ထောင်
Dividend
၃.၇၈%
Quarterly dividend
၀.၄၆ US$
Ex-dividend date
၂၀၂၆ နို ၁၂
P/E ratio
၁၇.၂၂
52-wk high
၆၁.၇၀ US$
52-wk low
၄၅.၈၀ US$
EPS
၂.၈၂ US$
Beta
၀.၂၀
Shares outstanding
၂၀၂.၂၇ ဋေ
No. of employees
၇ သောင်း
Open
၄၉.၀၃ US$
High
၄၉.၄၉ US$
Low
၄၈.၅၄ US$
Mkt. cap
ဋေ ၉.၈၃ ထ
Avg. vol.
၄.၈၂ သန်း
Volume
၈.၉၆ ထောင်
Dividend
၃.၇၈%
Quarterly dividend
၀.၄၆ US$
Ex-dividend date
၂၀၂၆ နို ၁၂
P/E ratio
၁၇.၂၂
52-wk high
၆၁.၇၀ US$
52-wk low
၄၅.၈၀ US$
EPS
၂.၈၂ US$
Beta
၀.၂၀
Shares outstanding
၂၀၂.၂၇ ဋေ
No. of employees
၇ သောင်း
News stories
From web sources and news partners
London South East
·
ပြီးခဲ့သည့် ၁ နာရီ
GSK's Velzatinib granted orphan drug designation in Japan for GIST
Zacks
·
ပြီးခဲ့သည့် ၁၉ နာရီ
GSK Wins FDA Approval for Nuvalent-Acquired Nelkarmi in Lung Cancer
Benzinga
·
ပြီးခဲ့သည့် ၂၁ နာရီ
GSK Marks Second Lung Cancer Drug Approval This Year
The Globe and Mail
·
ပြီးခဲ့သည့် ၁ ရက်
Barclays Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOEmma Walmsley | Emma Walmsley
Employees၆.၆၈ သောင်း
Founded၂၀၀၀ ဒီ ၂၇
Headquarters-
SectorHealth Care
Industry-
Websitegsk.com